No products in the cart.
Cetuximab NO1 Injection
$1.00
Cetuximab NO1 Injection, 100mg in 50mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology
Description
Cetuximab NO1 Injection Description
Product name: Cetuximab N01 injection (Datelai/Kelun Botai)
Packaging specification: 100mg (50ml) Product dosage form: injection Packaging unit: bottle/box
Approval number: National Medicine Standard S20250006 Drug code: 86982635000030
Manufacturer: Sichuan Kelun Botai Biopharmaceutical Co., Ltd.
Cetuximab is a chimeric mouse–human IgG1 monoclonal antibody that competitively binds to the extracellular domain of the Epidermal Growth Factor Receptor (EGFR/HER1), blocking activation by EGF and TGF and inhibiting downstream proliferation and survival signaling (MAPK, PI3K/Akt, Jak/Stat)it.wikipedia.org+8synapse.patsnap.com+8iiab.me+8. It also promotes receptor internalization, antitumor apoptosis, inhibits angiogenesis, and elicits antibody-dependent cellular cytotoxicity (ADCC)
In China, Kelun Botai’s Cetuximab NO1 is approved for research use only (NMPA S20250006). It’s included in clinical phase III trials for:
RAS wild type colorectal cancer (first-line)
Head and neck squamous cell carcinoma (with radiotherapy)
KRAS G12C-positive NSCLC
Cetuximab NO1 Injection Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Cetuximab NO1 Injection |
| Strength | 100mg cetuximab per 50mL |
| Formulation | IV infusion solution, sterile, preservative-free |
| Manufacturer | Sichuan Kelun Botai Biopharma Co., Ltd. |
| Approved For | NMPA S20250006 (research use) |
| Product Code | 86982635000030 |
| Storage Conditions | Store at 2–8°C; protect from light; do not freeze |
| Shelf Life | As labeled on packaging |
| Appearance | Clear, colorless protein solution |
| Administration | Intravenous infusion (research protocol only) |
| Intended Use | Laboratory research / analytical purposes only |
Cetuximab NO1 Injection Mechanism & Research Applications
EGFR blockade: Prevents ligand-induced activation and downstream signaling (MAPK, PI3K/Akt)
Receptor internalization: Leads to EGFR downregulation on tumor cells?creativebiolabs.net+6pmc.ncbi.nlm.nih.gov+6synapse.patsnap.com+6.
ADCC: Recruits immune effectors to kill EGFR-expressing cancer cells?pmc.ncbi.nlm.nih.gov+1synapse.patsnap.com+1.
Combination synergy: Enhances chemo- or radio-therapy efficacy and overcomes resistance in KRAS wild-type models.
Use cases in research:
KRAS wild-type colorectal cancer models
Head and neck carcinoma + radiotherapy studies
EGFR pathway signaling / resistance modeling
Testing in KRAS G12C and NSCLC models
Why Choose Cetuximab NO1 (Datalai)?
A locally produced biosimilar to Erbitux® with full regulatory traceability
Ideal for EGFR-pathway cancer research, ADCC assays, and combination therapy testing
Included in Phase III clinical pipelines for colorectal and lung cancer
Pre-filled injection format for reliable dosing in lab protocols
Panitumumab (EGFR antibody)
EGFR TKIs: Gefitinib, Erlotinib, Osimertinib
Radiolabeled EGFR tracers
Antibody–drug conjugates targeting EGFR
Summary
Cetuximab NO1 Injection (100mg/50mL) by Kelun Botai is a biosimilar EGFR antibody, approved for research in EGFR-driven cancers. It blocks receptor activation, mediates ADCC, and is crucial for preclinical oncology studies.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 26 × 25 × 26 cm |
1 review for Cetuximab NO1 Injection
Related products
Doxorubicin Liposome Injection
is a liposomal formulation of doxorubicin, offering enhanced circulation time and reduced cardiotoxicity compared to the traditional form. Supplied as 20mg per 10mL vial, it is strictly for laboratory research use only—not for clinical or human application. Please consult the staff for other purposes. $2.00Ivodazumab Injection (lvonescimab)
Ivodazumab (Yidafang) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00Elemene Injection
Elemene Injection is a traditional Chinese medicine–derived liposomal terpene mixture (elemene) approved in China (NMPA No. H20110114; Product Code 86909563000017). Supplied as a 10mL liposomal solution per vial (0.2g elemene), 5 vials per box. Intended strictly for laboratory and preclinical research purposes Please consult the staff for other purposes. $1.00Limertinib Tablets
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M mutated non small cell lung cancer, including patients with brain metastases. $1.00
JOHNEKA –
Pago recibido vía PayPal, gracias.